H.C. Wainwright upgraded Vor Bio (VOR) to Buy from Neutral with a $3 price target Vor’s board has strategically strengthened the “three pillars” needed to potentially increase the odds to become a commercial company in 24-30 months from now, the analyst tells investors. The firm is “encouraged by the quick resurrection of the company by the board and the management” after the company entered into an exclusive license agreement with RemeGen Co. to develop and commercialize telitacicept, the analyst added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.